Technology | March 22, 2007

ACC: ev3 Stent Cleared for Patients at Risk of Adverse Events from CAD Surgery

When used in conjunction with the ev3 embolic protection device, ev3’s PROTÉGÉ RX Carotid Stent has been FDA cleared for the treatment of carotid artery disease in patients who are at high-risk for adverse events from carotid artery surgery. The cleatance was supported by the CREATE (Carotid Revascularization with ev3 Inc. Arterial Technology Evolution) Trial demonstrating the safety and effectiveness of the PROTÉGÉ Stent and the SPIDER Embolic Protection Device when used together to treat carotid artery disease patients at risk for stroke and also at high-risk for adverse events from surgery.

The PROTÉGÉ RX is available in both straight and tapered stent configurations providing a variety of device options to address a broad range of patient anatomy present in carotid artery disease. The “rapid exchange” platform allows for a single physician to operate the device as compared to “over the wire” designs that require multiple operators.


Additional Content

News | Stents Carotid

June 26, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home June 26, 2023
Home
News | Stents Carotid

May 1, 2023 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home May 01, 2023
Home
News | Stents Carotid

December 13, 2022 — InspireMD, Inc., developer of the CGuard Embolic Prevention Stent System (EPS) for the prevention of ...

Home December 13, 2022
Home
News | Stents Carotid

August 3, 2022 — Research from Ochsner Health published in the Journal of the American College of Cardiology is likely ...

Home August 03, 2022
Home
News | Stents Carotid
February 28, 2022 – InspireMD, Inc., a global developer of the CGuard Embolic Prevention Stent System (EPS) device for ...
Home February 28, 2022
Home
Subscribe Now